Bio-equivalence of IR Tablet against ER Tablet [Design Issues]

posted by Jasim Uddin – Bangladesh, 2018-06-20 11:29 (945 d 08:35 ago) – Posting: # 18929
Views: 1,924

Dear Sirs

Does anyone know about BE Study design of Immediate Release Formulation against Extended Release Formulation?

We manufacture Potassium Chloride 600 mg IR tablet. But no RLD is available as IR tablet. RLD SLOW-K 600 mg of Novartis is available as ER tablet.

Is it possible to design BE study of our IR formulation of Potassium Chloride 600 mg against SLOW-K 600 mg ER tablet?

Would appreciate kind advice of the experts in this forum.

Kind regards

Jasim

Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

Activity
 Admin contact
21,308 posts in 4,444 threads, 1,489 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Wednesday 20:04 UTC (Europe/Vienna)

Power: That which is wielded by the priesthood of
clinical trials, the statisticians, and a stick which they use
to beta their colleagues.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5